NAVIDEA BIOPHARMACEUTICALS, INC. 4
4 · NAVIDEA BIOPHARMACEUTICALS, INC. · Filed Mar 11, 2014
Insider Transaction Report
Form 4
LARSON BRENT L
VP Finance and CFO
Transactions
- Exercise/Conversion
Common Stock
2014-03-10$0.49/sh+50,000$24,500→ 372,996 total - Sale
Common Stock
2014-03-10$1.96/sh−41,500$81,340→ 319,184 total - Tax Payment
Common Stock
2014-03-10$1.99/sh−12,312$24,501→ 360,684 total - Exercise/Conversion
Stock Option (Right to Buy)
2014-03-10−50,000→ 0 totalExercise: $0.49Exp: 2014-07-28→ Common Stock (50,000 underlying)
Holdings
- 93,217(indirect: By 401(k))
Common Stock
Footnotes (2)
- [F1]Sales were effected to generate funds required to cover tax obligations arising from expiring options or the vesting of shares of restricted stock. The transaction is matchable under Section 16(b) of the Securities Exchange Act with Mr. Larson's purchase of 5,000 shares of common stock at $1.39 per share on November 8, 2013. As a result, Mr. Larson will pay the company $2,850, representing the full amount of the profit realized in connection with the short-swing transaction.
- [F2]Option vests 1/3 of the underlying shares annually beginning on the first anniversary of the date of grant.